# A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

Study · id `cardio:ct-nct02119819` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02119819](<https://clinicaltrials.gov/study/NCT02119819>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02119819

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 420 participants.

## Technical summary

Registry record NCT02119819. Randomized; double masking; primary purpose treatment. Start 2014-04 (registry gives no type); primary completion 2015-08 (actual). Results posted on 2021-04-14.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 420 participants (enrolled count; ClinicalTrials.gov record NCT02119819, source copy `cardio:ctgov-nct02119819-2021-05-27`, retrieved 2026-10-26)
- Start date: 2014-04 (registry gives no type) (ClinicalTrials.gov record NCT02119819, source copy `cardio:ctgov-nct02119819-2021-05-27`, retrieved 2026-10-26)
- Primary completion: 2015-08 (actual) (ClinicalTrials.gov record NCT02119819, source copy `cardio:ctgov-nct02119819-2021-05-27`, retrieved 2026-10-26)
- Completion: 2015-10 (actual) (ClinicalTrials.gov record NCT02119819, source copy `cardio:ctgov-nct02119819-2021-05-27`, retrieved 2026-10-26)
- Results first posted: 2021-04-14 (ClinicalTrials.gov record NCT02119819, source copy `cardio:ctgov-nct02119819-2021-05-27`, retrieved 2026-10-26)
- Countries: United States; Greece; Mexico; Poland; Puerto Rico; Romania (ClinicalTrials.gov record NCT02119819, source copy `cardio:ctgov-nct02119819-2021-05-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02119819-2021-05-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): LY2944876
- Intervention (Drug): Exenatide extended-release
- Intervention (Drug): Placebo
- Intervention (Drug): Metformin
- Lead sponsor: OPKO Health, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: OPKO Health, Inc. (`cardio:org-opko-health-inc`)

## Provenance

Content hash: da161ea13d4452c0e87c3ad193c1f6e4c0fd25d4db053cba380b778b22fc2a3d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
